TABLE 3.
Effect of preexisting immunity to Adhu5 on vaccine efficacya
| Vaccine (dose [PFU]) | VNA titer (IU) (% survival upon challenge) with preexposure |
|
|---|---|---|
| None | Adhu5 | |
| Adhu5rab.gp (2 × 107) | 972 (100) | 486 (100) |
| Adhu5rab.gp (2 × 106) | 486 (100) | 54 (100) |
| Adhu5rab.gp (2 × 105) | 486 (100) | 18 (40) |
| AdC68rab.gp (2 × 107) | 729 (100) | 729 (100) |
| AdC68rab.gp (2 × 106) | 486 (100) | 486 (100) |
| AdC68rab.gp (2 × 105) | 54 (100) | 54 (100) |
| None | <0.5 (0) | |
a
Groups of five C3H/He mice were injected with 4 × 108 PFU of an E1-deletion-containing Adhu5 virus expressing the L1 protein of HPV-16. Mice were injected 3 weeks later with various doses of Adhu5rab.gp or AdC68rab.gp. Sera were harvested 2 weeks later and tested for VNAs to rabies virus. Mice were then challenged with 10 LD50 of CVS-11 virus, and survival was recorded.